18F-FDG PET/MRI可早期预测胰腺导管腺癌化疗反应
PURPOSE: In this prospective exploratory study, we evaluated the feasibility of [18F]fluorodeoxyglucose ([18F]FDG) PET/MRI-based chemotherapy response prediction in pancreatic ductal adenocarcinoma at two weeks upon therapy onset.…
要点
- 化疗开始后2周MTV50%升高≥20%或ADC升高≥15%预测反应。
- 化疗开始后2周TLG50%降低≤20%预测非反应。
- ∆TLG50%联合∆ADCmax或∆MTV50%联合∆ADCmax可改善区分。
核心结论
- 多参数18F-FDG PET/MRI衍生的肿瘤糖酵解和细胞密度变化指标可能实现极早期化疗反应预测。
研究设计与样本
- 所有患者在化疗前和化疗开始后2周行18F-FDG PET/MRI,3个月时按RECIST1.1评估反应。
主要发现
- 化疗开始后2周∆MTV50%和∆ADC分别升高≥20%和15%以及∆TLG50%降低≤20%可预测反应者和非反应者。
- 参数组合(∆TLG50%与∆ADCmax或∆MTV50%与∆ADCmax)进一步改善区分。
关键数值与推荐
- ∆MTV50%升高≥20%和∆ADC升高≥15%预测反应。
- ∆TLG50%降低≤20%预测非反应。
临床怎么用
- 对接受化疗的胰腺导管腺癌患者,可考虑在化疗开始后2周行18F-FDG PET/MRI多参数评估以早期预测反应。
局限性
- 作者建议在更大患者队列中进一步开展前瞻性研究以确定其临床影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this prospective exploratory study, we evaluated the feasibility of [18F]fluorodeoxyglucose ([18F]FDG) PET/MRI-based chemotherapy response prediction in pancreatic ductal adenocarcinoma at two weeks upon therapy onset. MATERIAL AND METHODS: In a mixed cohort, seventeen patients treated with chemotherapy in neoadjuvant or palliative intent were enrolled. All patients were imaged by [18F]FDG PET/MRI before and two weeks after onset of chemotherapy. Response per RECIST1.1 was then assessed at 3 months [18F]FDG PET/MRI-derived parameters (MTV50%, TLG50%, MTV2.5, TLG2.5, SUVmax, SUVpeak, ADCmax, ADCmean and ADCmin) were assessed, using multiple t-test, Man-Whitney-U test and Fisher's exact test for binary features. RESULTS: At 72 ± 43 days, twelve patients were classified as responders and five patients as non-responders. An increase in ∆MTV50% and ∆ADC (≥ 20% and 15%, respectively) and a decrease in ∆TLG50% (≤ 20%) at 2 weeks after chemotherapy onset enabled prediction of responders and non-responders, respectively. Parameter combinations (∆TLG50% and ∆ADCmax or ∆MTV50% and ∆ADCmax) further improved discrimination. CONCLUSION: Multiparametric [18F]FDG PET/MRI-derived parameters, in particular indicators of a change in tumor glycolysis and cellularity, may enable very early chemotherapy response prediction. Further prospective studies in larger patient cohorts are recommended to their clinical impact.
引用
- Harder FN, Jungmann F, Kaissis GA, et al. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Res. 2021. PMID: 34322781. doi:10.1186/s13550-021-00808-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。